Marshall Wace LLP lowered its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS – Free Report) by 81.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,831 shares of the company’s stock after selling 93,549 shares during the period. Marshall Wace LLP’s holdings in NewAmsterdam Pharma were worth $419,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Jennison Associates LLC acquired a new position in NewAmsterdam Pharma during the first quarter worth approximately $22,015,000. Artal Group S.A. purchased a new stake in NewAmsterdam Pharma in the 1st quarter valued at $18,920,000. Janus Henderson Group PLC purchased a new stake in NewAmsterdam Pharma in the 1st quarter valued at $15,018,000. Opaleye Management Inc. purchased a new position in NewAmsterdam Pharma during the 4th quarter worth $2,964,000. Finally, TimesSquare Capital Management LLC acquired a new position in NewAmsterdam Pharma in the first quarter valued at $5,407,000. 89.89% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other news, CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 19.50% of the stock is currently owned by company insiders.
Analyst Ratings Changes
Get Our Latest Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Price Performance
NASDAQ NAMS opened at $17.62 on Friday. NewAmsterdam Pharma has a 52-week low of $5.63 and a 52-week high of $26.35. The firm has a 50-day moving average price of $16.50 and a 200 day moving average price of $18.75.
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last issued its earnings results on Wednesday, August 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.08. The business had revenue of $2.28 million for the quarter, compared to analysts’ expectations of $2.20 million. On average, analysts predict that NewAmsterdam Pharma will post -2.06 EPS for the current year.
NewAmsterdam Pharma Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Articles
- Five stocks we like better than NewAmsterdam Pharma
- When to Sell a Stock for Profit or Loss
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Upcoming IPO Stock Lockup Period, Explained
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- The Risks of Owning Bonds
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.